[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5239 Introduced in House (IH)]

<DOC>






119th CONGRESS
  1st Session
                                H. R. 5239

To amend the Public Health Service Act to expand research and education 
      with respect to endometrial cancer, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           September 9, 2025

 Mr. David Scott of Georgia (for himself, Ms. Clarke of New York, Ms. 
 Brown, Mr. Johnson of Louisiana, Ms. Moore of Wisconsin, Ms. Norton, 
  Ms. Sewell, and Mr. Tonko) introduced the following bill; which was 
            referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
To amend the Public Health Service Act to expand research and education 
      with respect to endometrial cancer, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Endometrial Cancer Research and 
Education Act of 2025''.

SEC. 2. FINDINGS.

    Congress finds the following:
            (1) Endometrial cancer is cancer of the lining of the 
        uterus (or endometrium) and is the most common form of uterine 
        cancer.
            (2) Endometrial cancer is the fourth most common cancer 
        diagnosed in women, after breast, lung, and colon cancer.
            (3) Endometrial cancer mainly affects postmenopausal women, 
        with most women diagnosed between age 55 and 64.
            (4) Women with polycystic ovary syndrome (PCOS) and uterine 
        leiomyoma have an increased risk of developing endometrial 
        cancer.
            (5) Unlike most other types of cancer, the incidence of 
        endometrial cancer, particularly aggressive subtypes of such 
        cancer, has been increasing in the United States among all 
        women, particularly among African-American and Asian women, 
        with a 2.5 annual percent change for both groups.
            (6) In comparison to non-Hispanic White women, African-
        American women have significantly higher incidence rates of 
        aggressive endometrial cancers.
            (7) Such incidence rates for Hispanic and Asian women are 
        equal to or lower than such incidence rates for non-Hispanic 
        White women.
            (8) Although non-Hispanic White women are more likely to be 
        diagnosed with endometrial cancer in comparison to African-
        American women, the rate of mortality is higher for African-
        American women.
            (9) Currently, the cause of such disparity is unknown. 
        Researchers are proposing investigative studies that link this 
        disparity to the relationship between delays in care, 
        aggressive late-stage diagnosis, and the time between diagnosis 
        and beginning treatment protocol for their cancer type. These 
        factors are often exacerbated by socioeconomic conditions that 
        affect access to innovative treatment, treatment completion, 
        patient-reported outcomes, and overall quality of life.

SEC. 3. EXPANDING RESEARCH AND EDUCATION WITH RESPECT TO ENDOMETRIAL 
              CANCER.

    (a) National Institutes of Health.--Part B of title IV of the 
Public Health Service Act (42 U.S.C. 284 et seq.) is amended by adding 
at the end the following:

``SEC. 409K. ENDOMETRIAL CANCER.

    ``(a) In General.--The Director of NIH shall--
            ``(1) expand, intensify, and coordinate programs to conduct 
        and support research with respect to endometrial cancer;
            ``(2) communicate to medical professionals and researchers, 
        including through the endometrial cancer public education 
        program established under section 399V-8, the disparity in the 
        diagnosis of endometrial cancer between African-American women 
        and non-Hispanic White women and any new research relating to 
        endometrial cancer; and
            ``(3) ensure that African-American women are represented in 
        clinical trials conducted or supported by the National 
        Institutes of Health with respect to endometrial cancer in 
        appropriate proportion to incidence rates of such cancer for 
        African-American women.
    ``(b) Coordination With Other Institutes.--The Director of NIH 
shall coordinate activities carried out by the Director pursuant to 
subsection (a) with similar activities carried out by--
            ``(1) the Director of the Eunice Kennedy Shriver National 
        Institute of Child Health and Human Development;
            ``(2) the Director of the National Institute on Minority 
        Health and Health Disparities; and
            ``(3) the Director of the Office of Research on Women's 
        Health.
    ``(c) Authorization of Appropriations.--For purposes of carrying 
out this section, there is authorized to be appropriated $1,000,000 for 
each of fiscal years 2026 through 2028.''.
    (b) Centers for Disease Control and Prevention.--Part P of title 
III of the Public Health Service Act (42 U.S.C. 280g et seq.) is 
amended by adding at the end the following:

``SEC. 399V-8. ENDOMETRIAL CANCER PUBLIC EDUCATION PROGRAM.

    ``(a) In General.--The Secretary, acting through the Director of 
the Centers for Disease Control and Prevention, shall develop and 
disseminate to the public informational materials on endometrial 
cancer, including the incidence rate of such cancer, the risk factors 
for developing such cancer, the increased risk for ethnic minority 
women to develop such cancer, and the range of available treatments for 
such cancer. Any informational material developed pursuant to the 
previous sentence may be transmitted to a nonprofit organization; 
institution of higher education; Federal, State, or local agency; or 
media entity for purposes of disseminating such material to the public.
    ``(b) Inclusion.--The informational materials under subsection (a) 
shall include materials targeted toward African-American women.
    ``(c) Consultation.--In developing and disseminating informational 
materials under subsection (a), the Director of the Centers for Disease 
Control and Prevention shall consult with the Administrator of the 
Health Resources and Services Administration.
    ``(d) Authorization of Appropriations.--For purposes of carrying 
out this section, there is authorized to be appropriated such sums as 
may be necessary for each of fiscal years 2026 through 2028.''.
                                 <all>